Novartis AGcompleted the acquisition of Regulus Therapeutics Inc..
Novartis completes acquisition of Regulus Therapeutics
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders
Novartis to buy Regulus Therapeutics for up to $1.7 billion
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Should You Buy Regulus (RGLS) After Golden Cross?
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
4 Best Stocks To Buy Under $5
What Makes Regulus (RGLS) a New Buy Stock
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023